Literature DB >> 15302010

Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation.

Miguel Angel Gómez-Sánchez1, Carlos Saenz De La Calzada, Pilar Escribano Subías, Juan Francisco Delgado Jiménez, María Lázaro Salvador, Agustín Albarrán González, Luis Cea Calvo.   

Abstract

OBJECTIVE: To determine the acute vasodilator effect of sublingual sildenafil in heart transplant candidates with severe pulmonary hypertension due to severe left ventricular dysfunction (LVD).
BACKGROUND: Pulmonary hypertension confers an increased risk of early graft failure. PATIENTS AND METHODS: Seven patients, (mean age of 53+/-8) with severe LVD (mean EF: 19+/-1.7%, functional class III-IV) due to coronary artery disease, dilated cardiomyopathy and valvulopathy were evaluated for heart transplant. All patients presented a mean transpulmonary gradient >12 mmHg and pulmonary vascular resistances >2.5 W.U., despite full treatment for advanced heart failure. The following hemodynamic data were obtained at basal state and then 15, 30 and 45 min after administration of 100 mg of sublingual sildenafil: right atrial, mean pulmonary artery pressure (mPAP), mean pulmonary capillary wedge pressures, mean transpulmonary gradient (mTPG), blood pressure, cardiac output, pulmonary vascular resistances (PVR) and systemic vascular resistances. Sublingual sildenafil was given without changing the previous treatment of heart failure.
RESULTS: After 30 min of sublingual sildenafil, mPAP decreased from 37 (28-61) to 30 (16-42) mmHg and PVR decreased from 5.2 (1.9-13.8) to 2.5 (1.4-3.9) W.U. after 45 min. Mean TPG decreased from 19 (16-33) to 12 (8-14) mmHg at 45 min. Mean pulmonary capillary wedge pressure, cardiac output, systemic vascular resistances and mean blood pressure were unchanged. Sublingual sildenafil was well tolerated, with only transient facial flushing in 4 patients and mild headache in 2.
CONCLUSIONS: Based on this initial study, sublingual sildenafil may be a useful alternative drug to perform acute vasodilator test in heart transplant candidates with significant pulmonary hypertension due to severe LVD. Nevertheless, further studies are warranted to confirm our results.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302010     DOI: 10.1016/j.ejheart.2003.11.015

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  9 in total

1.  Sildenafil for noncompaction cardiomyopathy treatment in a child: case report.

Authors:  Ana Carolina Costa Redondo; Gabriela Fuenmayor; Karen Saori Shiraishi; Simone Rolim F Fontes; Patrícia Figueiredo Elias; Rogerio Souza; Ieda Biscegli Jatene
Journal:  Arq Bras Cardiol       Date:  2014-03       Impact factor: 2.000

2.  Giant, dissecting, high-pressure pulmonary artery aneurysm: case report of a 1-year natural course.

Authors:  Anton Smalcelj; Vojtjeh Brida; Miroslav Samarzija; Ante Matana; Eduard Margetic; Niksa Drinkovic
Journal:  Tex Heart Inst J       Date:  2005

3.  Approach to patients with heart failure and pulmonary hypertension.

Authors:  Paul R Forfia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

4.  Management of severe pulmonary hypertension in patients undergoing mitral valve surgery.

Authors:  Carlos D Davila; Paul R Forfia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-06

Review 5.  Evolving Concepts of Pulmonary Hypertension Secondary to Left Heart Disease.

Authors:  Bhavadharini Ramu; Thenappan Thenappan
Journal:  Curr Heart Fail Rep       Date:  2016-04

6.  PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support.

Authors:  Ryan J Tedford; Anna R Hemnes; Stuart D Russell; Ilan S Wittstein; Mobusher Mahmud; Ari L Zaiman; Stephen C Mathai; David R Thiemann; Paul M Hassoun; Reda E Girgis; Jonathan B Orens; Ashish S Shah; David Yuh; John V Conte; Hunter C Champion
Journal:  Circ Heart Fail       Date:  2008-11       Impact factor: 8.790

7.  Comparison of drugs for pulmonary hypertension reversibility testing: A meta-analysis.

Authors:  Maya Guglin; Shabnam Mehra; Thomas J Mason
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

8.  Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.

Authors:  Javier Bermejo; Raquel Yotti; Rocío García-Orta; Pedro L Sánchez-Fernández; Mario Castaño; Javier Segovia-Cubero; Pilar Escribano-Subías; José Alberto San Román; Xavier Borrás; Angel Alonso-Gómez; Javier Botas; María G Crespo-Leiro; Sonia Velasco; Antoni Bayés-Genís; Amador López; Roberto Muñoz-Aguilera; Eduardo de Teresa; José R González-Juanatey; Arturo Evangelista; Teresa Mombiela; Ana González-Mansilla; Jaime Elízaga; Javier Martín-Moreiras; José M González-Santos; Eduardo Moreno-Escobar; Francisco Fernández-Avilés
Journal:  Eur Heart J       Date:  2018-04-14       Impact factor: 29.983

9.  Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long-Term Survival.

Authors:  Javier Bermejo; Ana González-Mansilla; Teresa Mombiela; Ana I Fernández; Pablo Martínez-Legazpi; Raquel Yotti; Rocío García-Orta; Pedro L Sánchez-Fernández; Mario Castaño; Javier Segovia-Cubero; Pilar Escribano-Subias; J Alberto San Román; Xavier Borrás; Angel Alonso-Gómez; Javier Botas; María G Crespo-Leiro; Sonia Velasco; Antoni Bayés-Genís; Amador López; Roberto Muñoz-Aguilera; Manuel Jiménez-Navarro; José R González-Juanatey; Arturo Evangelista; Jaime Elízaga; Javier Martín-Moreiras; José M González-Santos; Eduardo Moreno-Escobar; Francisco Fernández-Avilés
Journal:  J Am Heart Assoc       Date:  2021-01-05       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.